Bio Path Holdings Inc (NASDAQ:BPTH)

1.55
Delayed Data
As of 3:59pm ET
 -0.06 / -3.73%
Today’s Change
1.54
Today|||52-Week Range
5.85
-23.46%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$19.5M

Company Description

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its platform DNAbilize, uses P-ethoxy, which is a deoxyribonucleic acid backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Maria Tari on May 10, 2007 and is headquartered in Bellaire, TX.

Contact Information

Bio-Path Holdings, Inc.
4710 Bellaire Boulevard
Bellaire Texas 77401
P:(832) 742-1357
Investor Relations:
(832) 742-1369

Employees

Shareholders

Other institutional7.67%
Individual stakeholders6.00%
Mutual fund holders1.82%

Top Executives

Peter H. NielsenChairman, President, CEO, CFO & Treasurer
Anthony PriceDirector-Finance & Accounting
Ana Maria TariResearch Director
Douglas P. MorrisSecretary & Non-Independent Director
Suzanne KennedyDirector-Corporate Development